A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma
Latest Information Update: 23 Dec 2021
At a glance
- Drugs Docetaxel (Primary) ; Ganetespib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms GALAXY-2
- Sponsors Synta Pharmaceuticals
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 12 Dec 2019 Results published in the Journal of Clinical Oncology
- 18 Aug 2016 This trial has been completed in Belgium as per European Clinical Trials Database record.